GHRH vs. GHRP: Growth Hormone Peptides Compared
By Charles Kamen, MD, board-certified neurologist
GHRH peptides and growth hormone secretagogues are both growth hormone-releasing hormone (GHRH) analogs used in peptide therapy. Dr. Charles Kamen, MD, board-certified neurologist at LiveNow Longevity in Las Vegas, explains the key differences to help patients understand their options. Individual results vary.
What Is Sermorelin?
Sermorelin is the first 29 amino acids of the 44-amino acid GHRH molecule. It retains the biological activity of full-length GHRH but has a shorter half-life, requiring more frequent administration. [1]
GHRH peptides were developed to treat growth hormone deficiency in children and has been used off-label in adult peptide therapy for decades.
What Is growth hormone secretagogues
growth hormone secretagogues are a GHRH analog modified to have a longer half-life than native GHRH or GHRH peptides. The modification allows it to bind to albumin in the bloodstream, extending its duration of action. [2]
This longer half-life means less frequent dosing while still stimulating growth hormone release.
Key Differences
The primary differences between GHRH peptides and growth hormone secretagogues are:
- Half-life: growth hormone secretagogues havesignificantly longer half-life (7-10 days vs. ~12 minutes for GHRH peptides)
- Dosing frequency: growth hormone secretagogues typically dosed 2-3x weekly; GHRH peptides requires daily or every-other-day dosing
- Albumin binding: growth hormone secretagogues binds albumin for extended release; GHRH peptides does not
- Potency: growth hormone secretagogues produces greater IGF-1 elevation in head-to-head studies
- History: GHRH peptides havelonger clinical history; growth hormone secretagogues are more recently developed
Which Is Better
Neither peptide is universally "better" — the choice depends on individual factors. Some patients prefer growth hormone secretagogues for its convenience and potency; others prefer GHRH peptides for its longer track record and daily dosing. [3]
Dr. Kamen discusses the tradeoffs with patients to determine the most appropriate option.
Combining with growth hormone secretagogues
Both GHRH peptides and growth hormone secretagogues are often combined with growth hormone secretagogues to enhance growth hormone release. The combination stimulates the pituitary through two different pathways — GHRH (via GHRH peptides or growth hormone secretagogues) and ghrelin receptor (via growth hormone secretagogues). [4]
Dr. Kamen develops combination protocols based on individual goals and tolerance.
Key Takeaways
- GHRH peptides and growth hormone secretagogues both stimulate growth hormone via GHRH pathway
- growth hormone secretagogues havelonger half-life and requires less frequent dosing
- GHRH peptides havelonger clinical history in peptide therapy
- growth hormone secretagogues produces greater IGF-1 elevation in comparative studies
- Both are often combined with growth hormone secretagogues for enhanced effects
- Dr. Kamen helps patients choose the most appropriate option
Common Questions
Is growth hormone secretagogues more effective than GHRH peptides?
Studies suggest growth hormone secretagogues produces greater IGF-1 elevation due to its longer half-life. However, both can be effective. The "best" choice depends on individual factors.
Can I switch from GHRH peptides to growth hormone secretagogues?
Yes. Patients may transition between peptides based on response, preference, and Dr. Kamen's recommendations.
What are the side effects of these peptides?
Side effects are generally mild and may include water retention, numbness/tingling, and headache. These are typically dose-dependent and resolve with adjustment.
How do I know which dose to use?
Dr. Kamen establishes dosing based on your goals, health status, IGF-1 levels, and response to therapy. Follow your prescribed protocol.
Can I use GHRH peptides or growth hormone secretagogues long-term?
Long-term use protocols vary. Some practitioners use cycling (periods on/off); others recommend ongoing therapy with monitoring. Dr. Kamen determines appropriate duration.
Do I need blood work while on these peptides?
Yes. Dr. Kamen monitors IGF-1 levels and other markers during peptide therapy to assess response and adjust dosing as needed.
Both GHRH peptides and growth hormone secretagogues are valid options for growth hormone optimization. Consult with Dr. Kamen to determine which peptide approach best fits your health goals.
References
- Prakash A, Goa KL. BioDrugs. 1999;12(2):139-157. (Sermorelin: a review of its use in growth hormone-releasing hormone therapy).
- Nair KS, et al. J Clin Endocrinol Metab. 2024;109(8):1989-2001.
- Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):45-53. (The safety and efficacy of growth hormone secretagogues).
- Bowers CY, et al. J Clin Endocrinol Metab. 1990;70(4):975-982. (GH-releasing peptide stimulates GH release in normal men and acts synergistically with GHRH).
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.